Published in Sci Transl Med on January 25, 2012
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes | NCT00378508
Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 3.41
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes (2012) 1.02
Regulatory T cells in autoimmune neuroinflammation. Immunol Rev (2014) 1.00
Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLoS One (2013) 0.97
T cells in the control of organ-specific autoimmunity. J Clin Invest (2015) 0.93
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J Autoimmun (2015) 0.91
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. PLoS Med (2016) 0.89
Thinking bedside at the bench: the NOD mouse model of T1DM. Nat Rev Endocrinol (2015) 0.88
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care (2014) 0.87
Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol (2014) 0.86
Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol (2015) 0.85
NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury. J Immunol (2014) 0.85
Inducing and Administering Tregs to Treat Human Disease. Front Immunol (2016) 0.84
Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus. Clin Exp Immunol (2013) 0.84
Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model. Clin Transl Immunology (2014) 0.81
Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J Immunol (2014) 0.81
Differential response of regulatory and conventional CD4⁺ lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action? J Immunol (2013) 0.80
Biomarkers in type 1 diabetes: application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes (2014) 0.80
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons. Islets (2013) 0.76
Intestinal Epithelial Cell Regulation of Adaptive Immune Dysfunction in Human Type 1 Diabetes. Front Immunol (2017) 0.75
Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol (2017) 0.75
Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. Wellcome Open Res (2017) 0.75
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med (2009) 5.25
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
Q-Gene: processing quantitative real-time RT-PCR data. Bioinformatics (2003) 3.71
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol (1997) 2.89
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol (2006) 2.49
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95
The habitual, diverse and surmountable obstacles to human immunology research. Nat Immunol (2008) 1.88
Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol (2009) 1.53
Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol (1989) 1.51
Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol (2004) 1.50
A mouse model for the human pathogen Salmonella typhi. Cell Host Microbe (2010) 1.46
Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation (1999) 1.43
Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci U S A (2010) 1.41
Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol (2010) 1.39
Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation (2009) 1.34
Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol (2010) 1.22
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat Rev Drug Discov (2011) 1.21
The highway code of T cell trafficking. J Pathol (2008) 1.19
Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol (2010) 1.14
Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol (2009) 1.11
Upregulation of CCL20 and recruitment of CCR6+ gastric infiltrating lymphocytes in Helicobacter pylori gastritis. Infect Immun (2007) 1.10
Murine skin transplantation. J Vis Exp (2008) 0.94
Human natural regulatory T cell development, suppressive function, and postthymic maturation in a humanized mouse model. J Immunol (2011) 0.94
Human T cell development in the liver of humanized NOD/SCID/IL-2Rγ(null)(NSG) mice generated by intrahepatic injection of CD34(+) human (h) cord blood (CB) cells. Clin Immunol (2011) 0.92
Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr (2007) 0.91
Remodeling rodent models to mimic human type 1 diabetes. Eur J Immunol (2009) 0.89
Oxidative stress enhances IL-8 and inhibits CCL20 production from intestinal epithelial cells in response to bacterial flagellin. Am J Physiol Gastrointest Liver Physiol (2010) 0.86
Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science (2005) 11.31
Inflammasomes in health and disease. Nature (2012) 6.75
Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med (2009) 5.77
A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. Science (2007) 4.86
Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature (2003) 4.60
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 4.23
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat Genet (2006) 3.57
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol (2005) 3.14
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog (2006) 3.04
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Impaired PtdIns(4,5)P2 synthesis in nerve terminals produces defects in synaptic vesicle trafficking. Nature (2004) 2.81
Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest (2007) 2.81
Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem (2005) 2.74
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin secretion in type 1 diabetes. Diabetes (2004) 2.59
Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes (2006) 2.52
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol (2007) 2.23
Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice. Neuron (2002) 2.21
Sequential MyD88-independent and -dependent activation of innate immune responses to intracellular bacterial infection. Immunity (2003) 2.20
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2006) 2.15
Natural history of beta-cell function in type 1 diabetes. Diabetes (2005) 1.98
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
Dual receptor T cells extend the immune repertoire for foreign antigens. Nat Immunol (2002) 1.96
Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med (2002) 1.94
Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow. Exp Hematol (2002) 1.88
Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. J Neurosci (2007) 1.88
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care (2007) 1.87
Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology (2013) 1.78
Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A (2011) 1.77
Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest (2013) 1.76
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A (2010) 1.73
Marrow-derived cells as vehicles for delivery of gene therapy to pulmonary epithelium. Am J Respir Cell Mol Biol (2002) 1.70
Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes (2008) 1.69
High resolution genetic mapping by genome sequencing reveals genome duplication and tetraploid genetic structure of the diploid Miscanthus sinensis. PLoS One (2012) 1.57
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol (2009) 1.53
Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes (2011) 1.52
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49
Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J Clin Invest (2015) 1.43
Plasmacytoid dendritic cells are productively infected and activated through TLR-7 early after arenavirus infection. Cell Host Microbe (2012) 1.42
The mutant leucine-zipper domain impairs both dimerization and suppressive function of Foxp3 in T cells. Proc Natl Acad Sci U S A (2006) 1.41
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol (2011) 1.39
TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis. Gastroenterology (2011) 1.39
Pillars Article: Sequence Analysis of Peptides Bound to MHC Class II Molecules. Nature. 1991. 353: 622-627. J Immunol (2016) 1.38
BID-D59A is a potent inducer of apoptosis in primary embryonic fibroblasts. J Biol Chem (2003) 1.34
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
FAT10/diubiquitin-like protein-deficient mice exhibit minimal phenotypic differences. Mol Cell Biol (2006) 1.32
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol (2003) 1.30
Chitinase 3-like-1 promotes Streptococcus pneumoniae killing and augments host tolerance to lung antibacterial responses. Cell Host Microbe (2012) 1.23
Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol (2010) 1.22
Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab (2008) 1.21
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat Rev Drug Discov (2011) 1.21
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes (2013) 1.19
Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke (2005) 1.19
The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol (2011) 1.14
Lymphotoxin-alpha- and lymphotoxin-beta-deficient mice differ in susceptibility to scrapie: evidence against dendritic cell involvement in neuroinvasion. J Virol (2002) 1.13
Apoptosome-independent activation of the lysosomal cell death pathway by caspase-9. Mol Cell Biol (2006) 1.12
Apoptosis is not required for mammalian neural tube closure. Proc Natl Acad Sci U S A (2009) 1.11
Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J Immunol (2011) 1.10
RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One (2012) 1.09
Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol (2005) 1.09
Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough. Ann N Y Acad Sci (2007) 1.08
Induction of TLR4-target genes entails calcium/calmodulin-dependent regulation of chromatin remodeling. Proc Natl Acad Sci U S A (2009) 1.06
Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol (2010) 1.06
In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med (2012) 1.01
Testicular immune privilege promotes transplantation tolerance by altering the balance between memory and regulatory T cells. J Immunol (2005) 1.01
Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype. Proc Natl Acad Sci U S A (2003) 1.01
Vγ4 γδ T cell-derived IL-17A negatively regulates NKT cell function in Con A-induced fulminant hepatitis. J Immunol (2011) 1.00
Macrophages sense and kill bacteria through carbon monoxide-dependent inflammasome activation. J Clin Invest (2014) 1.00
The role of AIRE in human autoimmune disease. Nat Rev Endocrinol (2010) 1.00
Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J Immunol (2009) 0.99
Gadd45 beta and Gadd45 gamma are critical for regulating autoimmunity. J Exp Med (2005) 0.99
Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. J Hepatol (2011) 0.98
Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose. Diabetes (2011) 0.98
Interaction of the c-Jun/JNK pathway and cyclin-dependent kinases in death of embryonic cortical neurons evoked by DNA damage. J Biol Chem (2002) 0.97
Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol (2010) 0.95
c-Jun N-terminal kinase 3 deficiency protects neurons from axotomy-induced death in vivo through mechanisms independent of c-Jun phosphorylation. J Biol Chem (2004) 0.95
Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev (2009) 0.95
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes (2013) 0.93
Analysis of β-cell death in type 1 diabetes by droplet digital PCR. Endocrinology (2014) 0.93